Drug Trial Radar · NCT03290248
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Nov 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Sep 19, 2017
Primary completion
Dec 21, 2018
Study completion Dec 21, 2018
Sponsor
- Lead sponsor
- AOBiome LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Orange County Research Center; Integrium
- First posted
- Sep 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis.
Conditions
- Allergic Rhinitis
- Allergic Rhinitis Due to Grass Pollen
- Healthy Volunteers
Interventions
B244 suspensionBiological
B244 suspension in 30ml/bottle
VehicleBiological
Vehicle, 30ml/bottle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: Baseline to Day 28
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Orange County Research Center
Tustin, California
Inflamax
Mississauga, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.